Inhibitory effects of hesperetin derivatives on guinea pig phosphodiesterases and Their ratios between high- and low-affinity rolipram binding

Journal of Pharmaceutical Sciences

Volumn 102, Issue 7, 2013, Pages 2120-2127

  Hsu, Hsin Te ^a   Wang, Wen Hung ^b   Han, Cheng Ying ^b   Chen, Chun Nan ^b   Chen, Chi Ming ^c   Ko, Wun Chang ^a,b  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

3 O triacetate; 3 O trimethylether; 7; Asthma; Chronic obstructive pulmonary disease (COPD); Enzymes; Hesperetin 5; In vitro model; Inhibition; Phosphodiesterase (PDE)3 4 inhibition; Pulmonary; Structure activity relationship (SAR)

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CYCLIC AMP; CYCLIC GMP; HESPERETIN; HESPERETIN 5,7,3' O TRIBUTYRATE; HESPERETIN 5,7,3' O TRIISOBUTYRATE; HESPERETIN 5,7,3' O TRIMETHYLETHER; HESPERETIN 5,7,3' O TRIPIVATATE; HESPERETIN 5,7,3' O TRIPROPIONATE; HESPERETIN 7 O ACETATE; HESPERETIN 7 O METHYLETHER; HESPERETIN 7,3' O DIACETATE; HESPERETIN 7,3' O DIMETHYLETHER; HESPERETIN-5,7,3' O TRIACETATE; HESPERIDIN; HESPERIDIN 3' O METHYLETHER; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; ROLIPRAM; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BINDING AFFINITY; BINDING SITE; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL GUINEA PIG; IC 50; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 84879028731     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23591     Document Type: Article

References (32)

1. Fan CK. 2006. Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533(1-3):110-117.
2. Torphy TJ. 1998. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157(2):351-370.
3. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA. 2003. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93(4):280-291.
4. Giembycz MA. 2000. Phosphodiesterase 4 inhibitors and the treatment of asthma: Where are we now and where do we go from here? Drugs 59(2):193-212.
5. 3H]-rolipram binding in guinea pig tissues. Invest New Drugs 26(5):417-424.
6. Ko WC, Shih CM, Lai YH, Chen JH, Huang HL. 2004. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem Pharmacol 68(10):2087-2094.
7. Yen KY. 1971. Pharmacology of common Chinese medicine III. Taipei, Taiwan: National Research Institute of Chinese Medicine, pp 20-24.
8. Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T, Aromaa A. 2002. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 76(3):560-568.
9. Shih CH, Lin LH, Hsu HT, Wang KH, Lai CY, Chen CM, Ko WC. 2012. Hesperetin, a selective phosphodiesterase 4 Inhibitor, effectively suppresses ovalbumin-induced airway hyperresponsiveness without influencing xylazine/ketamine-induced anesthesia. Evid Based Complement Alternat Med 2012. DOI:10.1155/2012/472897.
10. Furniss BS, Hannaford AJ, Smith PWG, Tatchell AK. 1989. Preparation of diazomethane, In Vogel's textbook of practical organic chemistry; Vogel AI, Tatchell AR, Furnis BS, Hannaford AJ, Smith PWG, Eds. New York: Longman Scientific and Technical with John Wiley & Sons, pp 432-433.
11. Kupchan SM, Bauerschmidt E. 1971. Cytotoxic flavonols from Baccharis sarothroides. Phytochemistry 10(3):664-666.
12. Jeong TS, Kim EE, Lee CH, Oh JH, Moon SS, Lee WS, Oh GT, Lee S, Bok SH. 2003. Hypocholesterolemic activity of hesperetin derivatives. Bioorg Med Chem Lett 13(16):2663-2665.
13. Ferte J, Kuhnel JM, Chapuis G, Rolland Y, Lewin G, Schwaller MA. 1999. Flavonoid-related modulators of multidrug resistance: Synthesis, pharmacological activity, and structure-activity relationships. J Med Chem 42(3):478-489.
14. Ko WC, Chen MC, Wang SH, Lai YH, Chen JH, Lin CN. 2003. 3-O-methylquercetin more selectively inhibits phosphodiesterase subtype 3. Planta Med 69(4):310-315.
15. Thompson WJ, Appleman MM. 1971. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10:311-316.
16. Ahn HS, Crim W, Romano M, Sybertz E, Pitts B. 1989. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol 38(19):3331-3339.
17. Podzuweit T, Nennstiel P, Muller A. 1995. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal 7(7):733-738.
18. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA. 1986. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: A receptor for new cardiotonic drugs. Mol Pharmacol 29(5):506-514.
19. Reeves ML, Leigh BK, England PJ. 1987. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J 241(2):535-541.
20. Gillespie PG, Beavo JA. 1989. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22, 948. Mol Pharmacol 36(5):773-781.
21. Schneider HH, Schmiechen R, Brezinski M, Seidler J. 1986. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127(1-2):105-115.
22. 3H]rolipram. J Pharmacol Exp Ther 305(2):565-572.
23. Yang YL, Hsu HT, Wang KH, Han CY, Chen CM, Chen CM, Ko WC. 2011. Hesperetin-7, 3′-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio. J Biomed Sci 18(1):84. DOI:10.1186/1423-0127-18-84.
24. 3H]rolipram binding. Biochem Pharmacol 51(7):949-956.
25. Yang YL, Hsu HT, Wang KH, Wang CS, Chen CM, Ko WC. 2012. Hesperidin-3′-O-methylether is more potent than hesperidin in phosphodiesterase inhibition and suppression of ovalbumin-induced airway hyperresponsiveness. Evid Based Complement Alternat Med 2012. DOI:10.1155/2012/908562.
26. Jin SL, Richter W, Conti M. 2007. Insights into the physiological functions of PDE4 from knockout mice. In Cyclic nucleotide phosphodiesterases in health and disease; Beavo JA, Francis SH, Houslay MD, Eds. Boca Raton: CRC Press, pp 323-346.
27. Hatzelmann A, Schudt C. 2001. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297(1):267-279.
28. Giembycz MA, Field SK. 2010. Roflumilast: First phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 4:147-158.
29. Underwood DC, Kotzer CJ, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW, Torphy TJ. 1994. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J Pharmacol Exp Ther 270(1):250-259.
30. Banner KH, Press NJ. 2009. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 157(5):892-906.
31. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 110(7):1045-1052.
32. Namgoong SY, Son KH, Chang HW, Kang SS, Kim HP. 1994. Effects of naturally occurring flavonoids on mitogen-induced lymphocyte proliferation and mixed lymphocyte culture. Life Sci 54(5):313-320.